Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Nicholas Pajewski PhD

Nicholas M. Pajewski PhD

Associate Professor of Biostatistics and Data Science, Division of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, North Carolina

Nicholas M. Pajewski, PhD, is an Associate Professor in the Department of Biostatistics and Data Science at Wake Forest University School of Medicine, where he is also the Director of Statistical Analytics for the Center for Health Care Innovation. Dr. Pajewski did his doctorate at the Medical College of Wisconsin, and a postdoctoral fellowship at the University of Alabama – Birmingham. He is a member of both the National Institute on Aging AD/ADRD Health Care Systems Research (IMPACT) Collaboratory and the National Coordinating Center for the Claude D. Pepper Older Americans Independence Centers. Dr. Pajewski is a biostatistician and clinical trialist with experience in large, multi-site randomized trials, largely focused on pharmacologic management of common chronic diseases in older adults. He has worked for almost a decade on the Systolic Blood Pressure Intervention Trial (SPRINT) evaluating more intensive blood pressure control, and is part of ongoing trials evaluating statin use in older adults free of cardiovascular disease (PRagmatic EValuation of evENTs And Benefits of Lipid-lowering in oldEr adults, PREVENTABLE) and the long term efficacy of phentermine in adults with obesity (Long term Effectiveness of the Antiobesity Medication Phentermine, LEAP).

Disclosures

No disclosures reported.